Mar De Miguel

2 days ago | bioworld.com | Mar De Miguel

Home » Epigenetics tells the story of aging blood cells BioWorld briefs for June 4, 2025. BioWorld MedTech briefs for June 4, 2025. The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its... BioWorld Asia briefs for June 3, 2025 It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic,...

4 days ago | bioworld.com | Mar De Miguel

CancerPan-cancer proteome atlas reveals new biomarkers and targetsAn international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22 cancer types, which has identified more than 9,000 proteins from 1,000 tumors. The results reveal which proteins allow for the classification of different cancer types, biomarkers and potential therapeutic targets, which are now available to the entire scientific community.

5 days ago | bioworld.com | Mar De Miguel

Drug design, drug delivery & technologiesDual-action synthetic peptides could fight superbugsA peptide with a dual mechanism of action – it dissolves the bacterial membrane and activates the immune system – could be an effective weapon against microorganisms that have evolved ways to evade antibiotics, as superbugs do.

1 week ago | bioworld.com | Mar De Miguel

Home » Epigenetics tells the story of aging blood cells BioWorld briefs for May 27, 2025. BioWorld MedTech briefs for May 27, 2025. BioWorld Asia briefs for May 27, 2025 A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company... Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...

2 weeks ago | bioworld.com | Mar De Miguel

Sanofi SA made good on its plan to bear down on M&A by agreeing to buy Vigil Neuroscience Inc. for $8 per share (NASDAQ:VIGL). Included in the transaction is a...